تداخل‌های دارویی
Nirsevimab + Palivizumab
شدت: متوسط
Nirsevimab and Palivizumab: moderate interaction.
آخرین به‌روزرسانی
ویژه کادر درمان — فقط جهت مرجع. این صفحه خلاصه‌ای کوتاه است، توصیه پزشکی نیست و جایگزین بروشور رسمی یا قضاوت بالینی نمی‌شود. پیش از تجویز یا تحویل دارو همیشه بررسی کنید.
محتوای بالینی این صفحه فقط به زبان انگلیسی موجود است.
خلاصه
Both are monoclonal antibodies that provide passive RSV protection and are used for the same indication. Giving both offers no added benefit and exposes the infant to unnecessary dosing.
معنای این تداخل به زبان ساده
Nirsevimab and Palivizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Nirsevimab belongs to Miscellaneous; Palivizumab belongs to Miscellaneous.
چرا رخ می‌دهد
Therapeutic duplication of RSV F-protein-targeting antibodies; no pharmacokinetic interaction is established.
اقدام لازم
Do not give palivizumab to infants who have already received nirsevimab in the same RSV season. For infants who had palivizumab first, follow the labeled guidance on switching.
از داروساز چه بپرسید
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
ویژه اعضای Pro+
باز کردن کل صفحه
یک حساب بسازید و دوره آزمایشی Pro+ را شروع کنید تا توصیه‌های کامل مدیریت Nirsevimab و Palivizumab، یادداشت‌های تکمیلی، جزئیات شواهد و بررسی‌کننده تداخل برای کل نسخه را باز کنید.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Pro+ را ۷ روز رایگان در وب امتحان کنید. بدون نیاز به کارت.
پرسش‌های متداول
Can I take Nirsevimab with Palivizumab?
MediHelp rates the interaction as moderate. Nirsevimab and Palivizumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Both are monoclonal antibodies that provide passive RSV protection and are used for the same indication. Giving both offers no added benefit and exposes the infant to unnecessary dosing.
How serious is the interaction between Nirsevimab and Palivizumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Do not give palivizumab to infants who have already received nirsevimab in the same RSV season. For infants who had palivizumab first, follow the labeled guidance on switching.
تک‌نگاری کامل، دوزاژ و بررسی تداخل دارویی در برنامه MediHelp
مرجع کامل را باز کنید، تداخل چند دارو را بررسی کنید و از ابزارهای دوز در برنامه MediHelp استفاده کنید.
